3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 3
3
Phase 1
3
Phase NA
2
Phase 2/3
2
Phase 4
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Hodgkin Disease
2
Breast Neoplasms
2
Anemia
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
lorlatinib
1
elemene
1
capmatinib
1
aumolertinib
1
aflutinib
1
Technetium Tc 99m Aggregated Albumin
1
Sunitinib
1
Sevoflurane
1
Radiotherapy
1
Propofol
1
Gefitinib
1
Fluorouracil
1
Craniotomy
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Carcinoma
×
Radiotherapy
×
Clear all
NCT00742222
2016-05-17
EXIBT
Xoft, Inc.
Phase 4
Completed
63 enrolled